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Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is associated with aberrant epigenetic regulation of the chromosome 4q35 D4Z4
macrosatellite repeat. The resulting DNA hypomethylation and relaxation of epigenetic repression leads to increased expression of the deleterious
DUX4-fl mRNA encoded within the distal D4Z4 repeat. With the typical late onset of muscle weakness, prevalence of asymptomatic individuals,
and an autosomal dominant mode of inheritance, FSHD is often passed on from one generation to the next and affects multiple individuals within
a family. Here we have characterized unique collections of 114 lymphoblastoid cell lines (LCLs) generated from 12 multigenerational FSHD
families, including 56 LCLs from large, genetically homogeneous families in Utah. We found robust expression of DUX4-fl in most FSHD LCLs
and a good correlation between DNA hypomethylation and repeat length. In addition, DUX4-fl levels can be manipulated using epigenetic drugs
as in myocytes, suggesting that some epigenetic pathways regulating DUX4-fl in myocytes are maintained in LCLs. Overall, these FSHD LCLs
provide an alternative cellular model in which to study many aspects of D4Z4, DUX4, and FSHD gene regulation in a background of low genetic
variation. Significantly, these non-adherent immortal LCLs are amenable for high-throughput screening of potential therapeutics targetingDUX4-fl
mRNA or protein expression.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Facioscapulohumeral muscular dystrophy (FSHD), affecting
~1:7500–15,000 individuals, is the most prevalent muscular
dystrophy that indiscriminately afflicts children and adults of all
ages and both genders [1–5]. All forms of FSHD are genetically
and epigenetically linked to the chromosome 4q35 D4Z4
macrosatellite array, with the interplay between these factors
accounting for much of the high variability in disease
penetrance and severity characteristic of the disease [1,6–15].
The predominant form of the disease, FSHD1 (OMIM 158900),
represents >95% of reported cases and results from large DNA
deletions within the 4q35 D4Z4 repeat array [16,17]. Healthy,
genetically unaffected individuals are typically defined as
having more than 10 D4Z4 repeat units (RUs) on both 4q
chromosome arms (generally 25–35 RUs and as high as 120
RUs per array [18,19]), whereas individuals with genetic
FSHD1 have a contracted D4Z4 array in the range of
1–10 D4Z4 RUs on one 4q chromosome arm, consistent with
an autosomal dominant mode of inheritance (Fig. 1) [20]. These
polymorphic FSHD1-sized D4Z4 contractions are not sufficient
for pathogenesis; development of FSHD also requires a disease
permissive allele of the chromosome 4q subtelomere (4A) in cis
with the contracted array [19,21–23]. FSHD2 (OMIM 158901),
the far less common form of FSHD, presents with similar
clinical features as FSHD1, but is caused by unlinked mutations
in genes encoding chromatin regulatory proteins [7,8,24,25].
However, FSHD2 is also genetically linked to the 4q35 array by
the requirement of at least one permissive 4A-type subtelomere
and a specific range of D4Z4 RUs (~11–28 RUs) in order to
develop disease [7,23]. Thus, with these genetic requirements,
FSHD2 is considered a digenic disease [8,25].
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Despite the clear genetic distinctions between these two
forms of FSHD, the effects on D4Z4 chromatin are quite
similar. In FSHD1, the 4q35 deletions result in the loss of
regulatory heterochromatin that significantly alters the local
epigenetic landscape of the contracted allele and is
characterized by allele-specific DNA hypomethylation
[12,26–30]. FSHD2 mutations reside in the genes encoding the
epigenetic machinery responsible for establishing and
maintaining repression of the D4Z4 arrays; therefore, FSHD2 is
characterized by DNA hypomethylation of both 4q35 D4Z4
arrays and often both 10q26 arrays as well [7,8,25]. Thus,
although epigenetic dysregulation is characteristic of FSHD in
general, FSHD1 and FSHD2 subjects can be distinguished from
each other and even individually diagnosed based on the DNA
methylation profiles of the 4q35 D4Z4 arrays and disease
permissive alleles [11,31,32]. In addition, some FSHD1
subjects may also have FSHD2-type mutations, with the
combined effect presenting as a very severe form of FSHD, thus
characterizing these genes as modifiers of disease severity [9].
To date, there have been two FSHD1 modifier genes identified,
SMCHD1 and DNMT3B [8,25], both of which encode
epigenetic regulator proteins, further highlighting the
importance of the 4q35 epigenetic status with respect to disease
presentation.
In both forms of FSHD, chromatin de-repression at the 4q35
D4Z4 macrosatellite has similar downstream molecular
consequences, resulting in the aberrant expression of a
pathogenic isoform of the DUX4 (double homeobox 4) gene,
DUX4-fl, in skeletal muscle [15,23,26,33–38]. Each D4Z4 RU
encodes a copy ofDUX4 [33]; however, onlyDUX4-fl produced
from the distal-most 4q35 D4Z4 RU is stably expressed in
FSHD. This is due to an array-distal polyadenylation signal
(PAS) in the noncoding exon 3 of DUX4, which is only present
in permissive 4q alleles (termed 4qA) [23,35]. This PAS is
required to stably expressDUX4mRNAs in somatic cells and is
essential for developing both forms of FSHD. However, the
DUX4 PAS is absent from about half of the 4q chromosomes
(4qB alleles) in the human population. These non-permissive
4qB chromosomes lack exon 3 of the DUX4 gene and are
therefore unable to generate polyadenylated DUX4 mRNA in
somatic cells, supporting the requirement for stable DUX4
expression in the development of FSHD [21,23,35,39,40].
Interestingly, the highly homologous chromosome 10q26 D4Z4
arrays have the A-type exon 3 sequence distal to the array;
however, the putativeDUX4 PAS is a sequence variant that does
not signal polyadenylation, thus explaining why D4Z4
contractions on chromosome 10 are not associated with FSHD
[21,23,39].
With the identification of DUX4 as the key pathogenic gene
in FSHD, the field is now engaged in designing DUX4-targeted
therapies [23,33,35,41,42]. Therapies can also be targeted
upstream of DUX4 expression, as the epigenetic disruption at
the FSHD locus is a major determinant in disease presentation
and progression. In addition, there are multiple genetic and
epigenetic modifiers of FSHD severity, which provide
additional therapeutic targets [7,9,12,25,36,43]. However, the
fundamental nature of FSHD presents several obstacles to
traditional drug development and screening (e.g., DUX4 is a
primate-specific gene expressed at very low levels primarily in
differentiated FSHD skeletal myocytes, which are not amenable
to high-throughput screening [35–37]). In addition, the high
variability of genetic and epigenetic features found among
FSHD patients can confound studies that are under-powered.
Thus, there is a great need in the field for large numbers of
well-characterized and freely available cohorts of cells, both
FSHD and related healthy controls, as well as the development
of readily screenable cellular models of FSHD. We and others
have previously shown that primary blood cells recapitulate the
epigenetic signature of the FSHD locus seen in skeletal
myocytes [26,31]. Here we perform an initial characterization
of 114 lymphoblastoid cell lines (LCLs) derived from healthy
and FSHD1 affected individuals from 12 multigenerational
families to provide valuable new tools for the FSHD field.
Previous studies using the genetically homogeneous families in
the Utah region have been informative in early clinical
descriptions and linkage studies for FSHD [20,44–48]. The
Fig. 1. Positions of restriction enzyme sites, probe, and PCR primers used to distinguish D4Z4 sequence. Scheme depicting the chromosome 4q35 D4Z4
macrosatellite array, which is contracted in FSHD1, leading to epigenetic changes specific to the contracted chromosome. De-repression of the pathogenic allele leads
to aberrant expression of the DUX4-fl mRNA from the distal-most D4Z4 repeat unit (RU). The 4q35 and 10q26 D4Z4 arrays are distinguished from each other by
combined EcoRI (E) + AvrII (B) digestion followed by Southern blotting and probing with p13E-11 (probe). DNAmethylation changes were assayed by BSS specific
for the distal D4Z4 RU of 4qA and its allelic variant 4qA-L [12] (gray bars) or all D4Z4 RUs (black bars).
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present study includes an updated genetic and molecular
characterization of 56 LCLs from six families in the Utah
cohort; thus, the availability of these LCLs, along with 58 LCLs
not known to be linked to the Utah cohort (although distant
linkage has not been excluded), may provide a wealth of new
information with respect to the role of familial genetic
background and the identification of factors that act as disease
modifiers [48]. Importantly, despite being immortalized and
non-myogenic, these cells represent useful models of FSHD-
dependent DUX4 expression that can be therapeutically
targeted and manipulated in a format suitable for high-
throughput drug screening.
2. Patients and methods
2.1. Subjects and cells
All cells used in this study are Epstein–Barr virus-
transformed B-LCLs generated in the laboratory of Stephen J.
Jacobsen at the University of California School of Medicine,
La Jolla, CA, USA and subjected to the same process for
immortalization. LCLs were transferred to the NIGMS Human
Genetic Cell Repository at the Coriell Institute for Medical
Research (CIMR) repository and are now available by catalog
using the Repository ID numbers (Table 1). Informed consent
was initially obtained from >600 participants from at least 36
families prior to the initial sample collection. Consent was
obtained a second time from each of the participants in this
study, allowing only the cells from these 114 reconsented
subjects to be transferred to and distributed by CIMR
for analysis. Subjects were examined by experienced
neuromuscular physicians for clinical weakness characteristic
of FSHD and diagnosed as either FSHD or healthy [44]. All
exams were performed and samples were collected between
1987 and 1992, prior to the discovery of the FSHD1 or FSHD2
genetic defects [8,16,17]; therefore, none of the subjects had
undergone genetic testing for FSHD at the time of sample
collection. The original clinical notes, other than the final
diagnosis of FSHD-affected or unaffected, were lost in the
process of salvaging and moving cell lines to CIMR. Therefore,
all cell lines have been kept in cryostorage and out of
circulation since their original derivation until they could be
properly validated and characterized for distribution.
2.2. Cell culture and drug treatment
LCL cultures were grown in suspension at 37 °C with 5%
CO2 in RPMI 1640 supplemented with 15% fetal bovine serum,
glutamine, and antimycotics. For drug treatments, 5-aza-2′-
deoxycytidine (ADC) (Sigma-Aldrich, #A3656) was added
daily to the LCL cultures at 5 μM final concentration for a total
of 3 days. Trichostatin A (TSA) (Sigma-Aldrich, #T1952) was
added to the cultures at 200 nM final concentration for the last
24 h prior to sampling.
2.3. D4Z4 deletion analysis
Genomic Southern blotting to identify subjects possessing
4q35 deletions was performed as described [49], and following
personal communication with Dr. Yukiko Hayashi. Briefly,
7.5 μg of LCL genomic DNA was digested overnight with
either EcoRI or both EcoRI and AvrII (New England Biolabs),
electrophoresed through a 0.3% agarose TAE gel for 36 h at
12 mAmps, denatured, and transferred to a nylon membrane.
Blots were probed with radiolabeled p13E-11 fragment [16]
and assessed for EcoRI restriction fragments that decreased in
size by 3.2 kb when combined with AvrII digestions, indicating
the particular fragment was from chromosome 4q [50,51]. AvrII
is an isoschizomer of BlnI, the enzyme traditionally used for
FSHD1 diagnosis to distinguish 4q35 D4Z4 arrays from the
BlnI-sensitive chromosome 10q26 D4Z4 arrays.
2.4. DNA methylation analysis
The DNA methylation status of the 4q35 D4Z4 array was
determined by bisulfite sequencing (BSS) analysis. BSS
analysis of the 4qA distal D4Z4 repeat unit was performed on
genomic DNAs isolated from LCLs, as described [12,31]. BSS
analysis for the distal D4Z4 repeat unit containing a B-type
subtelomeric region was performed using the MetB-For and
MetB-Rev PCR primers [30]. PCR products were cloned into
the pGEM-T Easy vector (Promega) for sequencing and
analyzed using web-based analysis software BISMA (http://
services.ibc.uni-stuttgart.de/BDPC/BISMA/) [52] with the
default parameters.
2.5. Chromosome 4q trace by Short Tandem Repeat analysis
(4qSTR analysis)
In order to confirm the position of each cell line in its
family pedigree and to trace inheritance of 4q D4Z4 repeats,
PCR-based 4qSTR analysis was performed using three STR
markers: D4S2930 and D4S1523 that have high heterozygosity
and most proximity to D4Z4 (900 kb and 500 kb, respectively),
and D4F104S1/SSLP (4q/10q STR marker) [53] (https://
www.urmc.rochester.edu/fields-center.aspx). For Family36,
D4S1652 was also analyzed to further identify parental origin
of 4q. Gender of each sample was also confirmed by STR
analysis of amelogenin [54].
2.6. Haplotyping and polyadenylation signal (PAS) analysis
Standard genomic PCR was performed on non-converted
LCL DNA and about 30% of each PCR reaction was run on
2% agarose gels to identify the 4qA, 4qA-L, and 4qB
chromosomes, as described [23]. The rest of the 4A and 4AL
PCR fragments were purified with a PCR purification kit
(Qiagen) and used for direct DNA sequencing to confirm PAS
and D4F104S1/SSLP haplotypes. Specific 4q and 10q
haplotypes were identified and assigned as described [22,40].
2.7. Gene expression analysis
Total RNA was prepared from each cell line using TRIzol
(ThermoFisher), as per manufacturer’s instructions, followed
by clean-up using the RNeasy mini kit (Qiagen). First strand
cDNA was generated from 2 μg total RNA using SuperScript
III reverse transcriptase and Oligo (dT)16 primer at 55 °C for
1 h. DUX4 expression was analyzed using nested PCR. For the
first reaction, 200 ng cDNA was amplified with primers DUX4
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Table 1
LCL characteristics.
Family Catalog No. Gender Genotype EcoRI/AvrII Clinical FSHD Genetic FSHD Epigenetic FSHD DUX4-fl expression
2 GM16250 M 4A161/4B163 22 kb (6RU) Yes Yes Yes 220.1
2 GM16251 F 4A161/4A161 NC No No No 0.2
2 GM16277 F 4A161/4C166H 22 kb (6RU) Yes Yes Yes 5.4
2 GM16275 F 4C166H/4B163 NC No No No 0.1
2 GM16276 F 4A161/4B163 NC No No No 1.6
2 GM16278 M 4A161/4C166H 22 kb (6RU) Yes Yes Yes 67.7
2 GM16279 M 4A161/4A161 22 kb (6RU) Yes Yes Yes 71.1
2 GM16280 F 4C166H/4B163 NC No No No 10.1
2 GM16281 F 4A161/4B163 NC No No No 0.4
2 GM16282 F 4A161/4A161 NC No No No 0.8
2 GM16283 F 4A161/4A161 22 kb (6RU) Yes Yes Yes 476.9
2 GM16284 F 4A161/4A161 NC No No No 0.2
2 GM16361 M 4A161/4A161 22 kb (6RU) Yes Yes Yes 158.7
2 GM16412 M 4A161/4C166H NC No No No 0.5
2 GM16427 M 4A161/4A161 22 kb (6RU) Yes Yes No 13.3
4 GM16285 F 4A161/4A161 22 kb (6RU) Yes Yes Yes 38.3
4 GM16286 F 4A161/4A-L161 22 kb (6RU) Yes Yes Yes 78.5
4 GM16287 M 4A161/4A161 22 kb (6RU) Yes Yes Yes 19.8
4 GM16288 M 4A161/4A-L161 22 kb (6RU) Yes Yes No 39.9
4 GM16289 F 4A161/4A-L161 NC No No No 0.1
4 GM16290b F 4A161/4A161 NC Yes No No 1.6
4 GM16291 F 4A161/4A161 22 kb (6RU) Yes Yes No 416.1
4 GM16292 F 4A-L161/4A-L161 NC No No No ND
4 GM16293 F 4A-L161/4A-L161 NC No No No ND
4 GM16294 F 4A161/4A161 22 kb (6RU) Yes Yes No 24.7
4 GM16295 M 4A161/4A161 NC No No No 0.7
6 GM16253 F 4A161/4A-L161 22 kb (6RU) Yes Yes Yes 69.3
6 GM16257 M 4A161/4B163 22 kb (6RU) Yes Yes Yes 10.5
6 GM16296 F 4A161/4B163 22 kb (6RU) Yes Yes Yes 76.7
6 GM16297 F 4A161/4A166 22 kb (6RU) Yes Yes Yes 1277.3
6 GM16298 F 4A161/4A-L161 22 kb (6RU) Yes Yes Yes 11.3
6 GM16299b F 4A-L161/4*168 NC Yes No No 0.0
6 GM16300 F 4A161/4B163 22 kb (6RU) Yes Yes Yes 12.4
6 GM16301 M 4B163/4B163 NC No No No 0.0
6 GM16302 F 4A161/4*168 22 kb (6RU) Yes Yes Yes 28.7
6 GM16303 M 4A-L161/4B163 NC No No No 0.0
6 GM16304 F 4A161/4A166 22 kb (6RU) Yes Yes Yes 208.3
6 GM16305 M 4C166H/4*168 NC No No No 0.0
6 GM16306 F 4A161/4A-L161 22 kb (6RU) Yes Yes Yes 24.5
6 GM16307 F 4A161/4*168 22 kb (6RU) Yes Yes Yes 1393.0
6 GM16308a M 4A161/4B163 22 kb (6RU) No Yes Yes 169.4
6 GM16309 F 4A161/4*168 22 kb (6RU) Yes Yes Yes 33.3
7 GM16310 M 4A161/4B163 NC No No No 0.2
7 GM16311 F 4A161/4B163 22 kb (6RU) Yes Yes No 24.7
7 GM16312 M 4A-L161/4*168 NC No No No ND
7 GM16313 M 4A-L161/4*168 NC No No No ND
7 GM16314 M 4A-L161/4A161 22 kb (6RU) Yes Yes Yes 4.1
7 GM16315 F 4*168/4*168 NC No No No 0.1
7 GM16316 M 4A-L161/4A161 NC No No No 0.2
7 GM16317 F 4A-L161/4A161 22 kb (6RU) Yes Yes Yes 240.7
7 GM16318 F 4A161/4*168 22 kb (6RU) Yes Yes Yes 208.9
7 GM16319 F 4A-L161/4*168 NC No No No 0.1
11 GM16320 F 4C166H/4*162 NC No No No 0.1
11 GM16321 F 4A161/4C166H 22 kb (6RU) Yes Yes No 111.5
11 GM16322b M 4A161/4C166H NC Yes No No 0.1
11 GM16324b F 4A-L161/4C166H NC Yes No No 0.4
11 GM16325 F 4A-L161/4A166 NC No No No 0.0
11 GM16413 M 4A161/4A-L161 22 kb (6RU) Yes Yes Yes 46.7
11 GM16414 F 4A161/4C166H 22 kb (6RU) Yes Yes Yes 2928.5
11 GM16415 M 4A-L161/4C166H NC No No No 0.1
11 GM16416a M 4A161/4*162 22 kb (6RU) No Yes Yes 72.8
(continued on next page)
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Table 1 (continued)
Family Catalog No. Gender Genotype EcoRI/AvrII Clinical FSHD Genetic FSHD Epigenetic FSHD DUX4-fl expression
11 GM16418 F 4A-L161/4C166H NC No No No 0.1
11 GM16428 M 4A-L161/4A161 NC No No No 0.2
11 GM16429a M 4A-L161/4A161 22 kb (6RU) No Yes Yes 199.1
11 GM16430a M 4A161/4*162 22 kb (6RU) No Yes Yes 19.5
11 GM16417 M 4A161/4C166H 22 kb (6RU) Yes Yes No 28.8
12 GM16326 M 4A161/4B165 22 kb (6RU) Yes Yes No 7.7
12 GM16327 F 4A161/4A161 22 kb (6RU) Yes Yes Yes 312.3
12 GM16328 M 4A161/4B165 NC No No No 0.1
12 GM16419 M 4A161del/4*165 NC No No ND 0.1
12 GM16420 M 4A161/4A161 22 kb (6RU) Yes Yes Yes 26.7
12 GM16421 F 4A161/4A161 NC No No No 0.2
12 GM16422 M 4A161/4A161 22 kb (6RU) Yes Yes No 382.9
15 GM16329 M 4A161/4A166 22 kb (6RU) Yes Yes No 203.1
15 GM16130 F 4A161/4A161 22 kb (6RU) Yes Yes Yes 147.2
15 GM16331 M 4A161/4C166H NC No No No 0.2
15 GM16332 F 4C166H/4B163 NC No No No 0.2
15 GM16333 F 4A161/4B163 22 kb (6RU) Yes Yes Yes 65.5
18 GM16334 F 4A161/4A166 18 kb (5RU) Yes Yes Yes 1668.3
18 GM16335 M 4A161/4A-L161 NC No No No 0.3
18 GM16336 F 4A161/4A-L161 18 kb (5RU) Yes Yes Yes 1468.1
18 GM16337 F 4A161/4A-L161 18 kb (5RU) Yes Yes Yes 535.3
25 GM16338 F 4A161/4A161 23 kb (6RU) Yes Yes No 56.9
25 GM16339a F 4A-L161/4A161 23 kb (6RU) No Yes Yes 163.1
25 GM16340 M 4A161/4B163 NC No No No 0.1
25 GM16341 M 4A-L161/4B163 NC No No No 0.2
32 GM16100 F 4C166H/4B163 NC No No No 3.0
32 GM16342 M 4A161/4A166 22 kb (6RU) Yes Yes No 39.5
32 GM16258 M 4A161/4B163 22 kb (6RU) Yes Yes No 4.9
32 GM16343 M 4A161/4C166H 22 kb (6RU) Yes Yes Yes 613.9
32 GM16431b M 4C166H/4A166 NC Yes No No 12.5
33 GM16101 F 4A-L161/4*162 NC No No No 0.3
33 GM16126 F 4A-L161/4A166 33 kb (9RU) Yes Yes Yes 19.7
33 GM16131 M 4A161/4A161 22 kb (6RU) Yes Yes Yes 59.2
33 GM16154 M 4A161/4*162 22 kb (6RU) Yes Yes No 1.5
33 GM16254a F 4A-L161/4A166 33 kb (9RU) No Yes No 318.3
33 GM16259 M 4A-L161/4A161 22 kb (6RU) Yes Yes Yes 30.3
33 GM16354 F 4A-L161/4A166 33 kb (9RU) Yes Yes Yes 248.5
33 GM16344 F 4A161/4*162 NC No No No 0.3
33 GM16345 F 4A-L161/4A161 22 kb (6RU) Yes Yes No 85.4
33 GM16355 F 4A-L161/4A166 NC No No No 0.2
33 GM16425a F 4A166/4*168 33 kb (9RU) No Yes No 1.0
33 GM16426 M 4A-L161/4A161 NC No No No 0.2
33 GM16357 M 4A166/4*168 NC No No No 0.2
33 GM16423 F 4A161/4*162 22 kb (6RU) Yes Yes No 41.5
33 GM16424a F 4A166/4A166 33 kb (9RU) No Yes No 8.4
33 GM16353 F 4A-L161/4*162 NC No No No 0.3
33 GM16356 M 4A-L161/4A166 NC No No No 0.1
36 GM16347 M 4B163/4B168 NC No No No 0.0
36 GM16348 F 4A-L161/4B168 16 kb (4RU) Yes Yes Yes 1.1
36 GM16349 F 4B163/4B168 NC No No No 0.0
36 GM16350 F 4A-L161/4B163 NC No No No 0.0
36 GM16351 M 4A-L161/4B168 16 kb (4RU) Yes Yes No 1.0
36 GM16352 F 4A166/4B163 NC No No No 0.3
NA GM16330 ND 4A161/4B163 NC ND No No 0.2
EcoRI/AvrII (equivalent to EcoRI/BlnI) below 37 kb considered contracted allele and genetic FSHD1; DNA methylation of the distal D4Z4 gene body <35%
considered epigenetic FSHD; clinical notes from physician listing FSHD considered clinical FSHD (if FSHD was not noted, considered healthy). DUX4-fl mRNA
expression shown as fold expression compared to the lowest expressing FSHD1 LCL (GM16154), which was set to 1X. NC (Non-Contracted 4qA), ND (Not
Determined), NA (information is Not Available).
* Cannot determine 4A or 4B for this haplotype.
a Indicates asymptomatic FSHD1.
b Indicates clinical diagnosis of FSHD is not supported by genetic or epigenetic testing.
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For and DUX4 Rev2 in 1X GC Buffer supplied with Phusion
Hot Start II DNA Polymerase (Thermo Fisher) and cycled 10
times at 98 °C for 15 sec, 64 °C for 20 sec, and 72 °C for
15 sec. For the quantitative reaction, 5% of the first reaction was
amplified by qPCR using 1X IQ SYBR mix (BioRad) and
primers DUX4 For and DUX4 Rev with cycling parameters
95 °C for 10 sec, 64 °C for 15 sec, and 72 °C for 20 sec, with
readings taken at 86 °C for 10 sec. Expression of DUX4 target
genes was analyzed by qPCR using 5–10 ng cDNA, as
described [55]. Expression of all genes was normalized to 18S
rRNA, analyzed by qPCR using 5 ng of cDNA. All
oligonucleotide primer sequences for DUX4, downstream
targets, and 18S rRNA are previously reported [37]. Some
DUX4-fl qPCR products were purified with a PCR purification
kit (Qiagen) and used for direct DNA sequencing to confirm
haplotype.
3. Results
3.1. Genetic characterization of FSHD1 in cohorts of LCLs
We have characterized and validated 114 LCLs originally
obtained from 12 multigenerational FSHD-affected families
and validated them as genetically FSHD1 or healthy (Figs. 2–7,
Fig. A.1). Six of the families (Families 2, 7, 11, 12, 25, and 33)
originate from a historically informative region of Utah
[20,44,48], and six families have no known relationship to the
Utah cohort. Family pedigrees and diagnosis with respect to the
presence of clinical FSHD were available for each cell line.
However, samples were collected and LCLs were generated
more than 25 years ago by a third party; therefore, we first
evaluated the position of each LCL on the accompanying
pedigrees by identifying the gender and parental origin of 4q
chromosomes using short tandem repeat (STR) markers
(D4S2930, D4S1523, and D4F104S1). Overall, the identities of
the cell lines with respect to their placement within families and
throughout the pedigrees were >99% accurate and only one of
the 114 cell lines, GM16330, could not be placed in a pedigree.
We conclude that despite the minimal records available, these
113 cell lines are accurately represented by the accompanying
pedigrees. We have no information on the accuracy of the
clinical diagnosis for additional subjects whose cell lines were
not available (NA on the pedigrees), nor do we know if the
pedigrees are complete representations of all members of each
generation in a particular family.
All subjects were evaluated for signs of FSHD [44] and
clinical samples from which LCLs were derived were collected
between 1987 and 1992, prior to the availability of genetic or
epigenetic testing for FSHD. Thus, at the time of collection,
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Fig. 2. Pedigree for Family 2 from southern Utah. Families 7 and 11 (Fig. 3) are related as indicated. Those subjects determined by Southern blotting to be FSHD1
are indicated in black, with the contracted chromosome in red. The clinical diagnosis of FSHD is labeled. Relations were confirmed by 4qSTR analysis and 4q
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none of the subjects was genetically tested to confirm a
diagnosis of FSHD1 or FSHD2. Therefore, we analyzed each
LCL from these family cohorts for FSHD-permissive 4q
haplotypes, the presence of a 4qA PAS, and the presence of
FSHD1-sized 4q35 D4Z4 arrays (Table 1 and Table S1)
[16,17,23,30,40,49]. Linear Southern blot analysis of EcoRI
and EcoRI/AvrII digested genomic DNA performed with the
p13E-11 probe [56] identified 66 LCLs that contain contracted
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Fig. 4. Pedigrees for unrelated Families 6, 12, and 15. See figure legends for Figs. 2 and 3.
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4q35 D4Z4 arrays with EcoRI/AvrII fragments below the 37 kb
cutoff for FSHD1 (10 RUs) and ranging in size from 16 kb (4
RU) to 33 kb (9 RU), as shown in Table 1 and Table S1.
Chromosome 4q haplotyping determined that 63 of these LCLs
with contracted alleles have a predicted FSHD-permissive 4qA
subtelomere and the exon 3 PAS. Overall, the genetic
characterizations indicated that 63 cell lines met the standard
genetic criteria for FSHD1. For the remaining 3 cell lines
(GM16349, GM16350, and GM16352) with FSHD1-sized
D4Z4 contractions (33 kb), all from Family 36, the contracted
arrays were found on non-permissive 4qB chromosomes, with
no PAS detected, and were therefore genetically characterized
as healthy controls [39]. Interestingly, none of these three
subjects was clinically classified as FSHD; however, two other
members of Family 36, GM16348 and GM16351, who were
clinically diagnosed with FSHD, were confirmed to have
FSHD1-sized D4Z4 contractions (16 kb) on FSHD-permissive
4qA chromosomes. Thus, this one family illustrates the
requirement for both a contracted 4q allele and the permissive
4qA exon 3 PAS for developing FSHD. The remaining 48 LCLs
did not meet these FSHD1 genetic criteria and were therefore
classified as healthy controls, bringing the total number of
control LCLs to 51.
FSHD1 displays an autosomal dominant mode of
inheritance with incomplete and variable penetrance [13,20].
Including the FSHD1 genetic diagnosis for each subject on the
pedigrees showing multiple affected generations in all families
(e.g., 6 affected generations in Family 18, Fig. A.1) clearly
reveals this autosomal dominant mode of inheritance
(Figs. 2–7, Fig. A.1). Interestingly, the pedigrees accompanying
the LCLs provided a limited clinical diagnosis for each subject
with respect to FSHD presentation (either healthy or affected).
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Fig. 5. Pedigrees for unrelated Families 4, 18, and 25. See legend for Fig. 2.
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Although the specific criteria for each individual clinical
diagnosis in this study are not known, previous published work
by the coordinating physician, Dr. S. J. Jacobsen, described the
FSHD diagnostic criteria his group used at the time [44]. We
compared the recorded clinical diagnosis of FSHD with our
genetic diagnosis of FSHD1 and found a strong correlation
(55/63). However, 8/63 LCLs from four families (Family 6:
GM16308; Family 11: GM16416, GM16429, GM16430;
Family 25: GM16339; Family 33: GM16254, GM16424,
GM16425) that fit the genetic FSHD1 criteria were derived
from subjects that did not show any clinical signs of FSHD at
the time of their neuromuscular examination and blood
donation, suggesting that these subjects are FSHD1 carriers. In
addition, the FSHD1 EcoRI/AvrII deletion sizes (22–33 kb or
6-9RU) for each of these subjects are within the range reported
for asymptomatic FSHD1 [11,12,14,36]; therefore, these 8
subjects are considered in this study to be asymptomatic. It is
possible that these subjects were examined prior to developing
clinical FSHD, which is typically diagnosed in males by age 20
and females by age 30. Fortunately, the identifying information
provided with these samples allowed us to determine the age,
within ~4 years, at which each designated asymptomatic
subject was analyzed. Six of the subjects were >24 years old,
with the oldest being >65 years, and two of the subjects from
Family 11 (GM16416 and GM16430), both brothers, were <20
years old. The designation for these two youngest
asymptomatic subjects raises the concern that they had yet to
manifest noticeable symptoms. However, these brothers have
two FSHD-affected siblings who were also <20 years old,
indicating that FSHD can present at a young age in this family.
Interestingly, among these four genetically FSHD1 siblings, the
two affected subjects inherited the same nonpathogenic
chromosome from their mother while the two asymptomatic
subjects inherited the other nonpathogenic maternal
chromosome (Fig. 3), suggesting the nonpathogenic
chromosome 4q allele may be contributing to disease
presentation. Overall, the 8 asymptomatic LCLs in this study
may prove to be informative in the future identification of
disease modifiers, although caution should always be used in
the interpretation of data from asymptomatic lines, particularly
from younger subjects.
3.2. Correlation between DNA methylation levels and 4q35
D4Z4 repeat length in FSHD1 LCLs
FSHD is ultimately caused by the disruption of epigenetic
regulation governing the chromosome 4q35 D4Z4
macrosatellite array, combined with an FSHD-permissive 4q35
PAS, resulting in the pathogenic expression of the DUX4 gene
[15,26,35,57]. In FSHD1, the epigenetic disruption is caused by
the loss of large regions of regulatory heterochromatin.
However, it is well established that certain FSHD1-sized
deletions (6–10 D4Z4 RUs) can exist in different epigenetic
states that correlate with clinical presentation [11,12,32]. In
addition, genetic mutations in epigenetic modifiers of the D4Z4
array, typical of FSHD2, can also affect the epigenetic status
and clinical manifestation of disease in FSHD1 subjects [9,25].
Although FSHD is a myopathy, the epigenetic status of the
disease locus is similar between myogenic cells and peripheral
blood leukocytes isolated from the same individual [26,31]; it is
not known if immortalized LCLs similarly maintain the
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Fig. 6. Pedigrees for unrelated Families 32 and 36. See legend for Fig. 2.
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epigenetic status of this locus in the cells from which they were
derived. Studies assessing global DNA methylation levels in
LCLs compared with primary blood cells have reported both
similarities and differences, thus necessitating caution in the
interpretation of epigenetic profiles from LCLs [58–60].
Therefore, in addition to screening for FSHD1-sized deletions,
we characterized the epigenetic status of this cohort of cells by
assaying the DNA methylation levels of the region using FSHD
diagnostic bisulfite sequencing (BSS) [12,31] (Figs. A.2 and
A.3).
Genomic DNA isolated from primary cells, saliva, or
peripheral blood leukocytes of FSHD1 subjects displays <35%
DNA methylation on the distal D4Z4 RU of the contracted 4qA
allele when assayed using our chromosome 4qA-specific BSS
assay [12,31]. BSS analysis of FSHD1 LCLs revealed that
42/63 had levels of DNA hypomethylation considered
diagnostic for FSHD1 (<35% methylation) (Table S1). All
eleven families produced at least one LCL with FSHD1 levels
of DNA methylation, while four families (Family 6, 12/12;
Family 18, 3/3; Family 2, 6/7; Family 7, 3/4) showed a
consistently strong correlation between having an FSHD1
deletion and DNA hypomethylation. Interestingly, the
remaining 21 LCLs from FSHD1 subjects across seven families
showed a lack of concordance between DNA methylation and
disease manifestation among cells derived from individuals
containing the same deletion. For example, in Family 25,
GM16338 was derived from a subject that exhibited clinical
signs of FSHD, yet had >57% methylation, while GM16339
was derived from their daughter who had yet to show any
symptoms of FSHD despite ~5% DNA methylation in her
LCLs. Since the D4Z4 deletion is the same within each family,
this lack of concordance between DNA methylation levels and
disease manifestation suggests the presence of a mutation in a
modifier gene or differences in other underlying genetic
conditions that could account for this, such as overall D4Z4
content.
In contrast to the FSHD1 LCLs, none of the cell lines
derived from healthy subjects displayed FSHD1 levels of DNA
hypomethylation (0/51; n = 44 hypermethylated >35% and
n = 7 no 4qA BSS product). However, 3 LCLs from healthy
members of Family 36 (GM16349, GM16350, GM16352)
contained contracted 4q35 D4Z4 arrays with non-permissive
4qB alleles (Fig. 6, Table S1). Since all six members of this
family had at least 1 4qB allele, this family provided an
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and one with 9RUs (blue).
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opportunity to investigate the epigenetics of 4qB D4Z4 arrays.
We performed 4qB-specific BSS on the 6 LCLs from Family
36 (Fig. A.2) and found that the 3 healthy LCLs with
contracted 4qB alleles displayed FSHD1-like levels of
DNA hypomethylation (GM16349, Q1 = 7.1%; GM16350,
Q1 = 0.0%; GM16352, Q1 = 0.0%) as compared with the non-
contracted 4qB alleles with healthy levels of DNA methylation.
These data support the hypothesis that the physical removal of
heterochromatin at D4Z4 arrays causes the epigenetic
disruption in FSHD1 [15,26,28,57]. In addition, these data
provide further support for the unifying model for FSHD [23],
again confirming that a 4q35 D4Z4 contraction alone is not
causal for FSHD, but requires a permissive 4qA subtelomere in
cis to cause disease [39].
We next sought to investigate the potential for these FSHD1
cell lines to possess FSHD2-type modifier mutations. Since
these mutations result in hypomethylation of both alleles at 4q
and 10q [9,25], we analyzed all FSHD1 LCLs using our D4Z4
5′ BSS assay that analyzes the methylation status of all 4q and
10q D4Z4 RUs [31]. For each LCL, we found large differences
in DNA methylation among all 4q and 10q D4Z4 RUs
(Table S1), strongly suggesting that these subjects do not have
known FSHD2-type modifier mutations, although we cannot
rule out that the immortalization procedure and/or culturing
conditions and selection may play a role in these epigenetic
differences. While a comprehensive search for modifier
mutations in SMCHD1, DNMT3B, and elsewhere in the
genome is beyond the scope of this study, this cohort of cell
lines with appropriate family controls will be useful for
addressing these types of questions. Overall, we conclude that
many, but not all, LCLs exhibit the appropriate healthy or
FSHD1 DNA methylation profiles, and that this large cohort
displays genetic and epigenetic characteristics that may be
useful for investigating certain lines of inquiry pertinent to
FSHD.
FSHD1 LCLs display robust and variable expression of
DUX4-fl, which correlates with expression of DUX4-FL target
genes. To further assess the utility of these cells, we performed
targeted gene expression analysis. The loss of transcriptional
repression at the disease locus in FSHD results in the aberrant
stable expression of the pathogenic DUX4-fl mRNA in skeletal
muscle, due in part to the presence of two DUX4 myogenic
enhancers [37]. Although LCLs are not myogenic, DUX4-fl
expression has also been reported in non-myogenic cells [35].
Therefore, we analyzed DUX4-fl mRNA expression by qRT-
PCR in all cell lines (Fig. 9). We readily detected robust levels
of DUX4-fl mRNA in all 61 of the 4A161 contracted FSHD1
LCLs; however, the relative expression levels were highly
variable within families and across the entire cohort, displaying
a nearly 3000-fold range among all FSHD1 samples (Table 1).
In contrast, DUX4-fl expression, when reliably detected at all,
was generally very low in the healthy LCLs (Table 1), only five
of which displayed DUX4-fl levels above the lowest FSHD1
level. Three of these lines (GM16276, GM16290, and
GM16100) expressed 3-fold or less DUX4-fl expression
compared to the lowest-expressing FSHD1 line, which is lower
expression than 59 of the 61 FSHD1 LCLs, while DUX4-fl
levels in GM16280 (10.1-fold) and GM16431 (12.5-fold) were
still in the bottom 20% compared to the FSHD1 cells. Overall,
FSHD1 LCLs expressed on average >300-fold more DUX4-fl
mRNA than the healthy control LCLs. Variability among
FSHD1 cell lines and slight overlap in expression levels
between a few healthy LCLs and the lowestDUX4-fl expressing
FSHD1 LCLs likely reflect individual differences between
donor subjects and are consistent with the DUX4-fl mRNA
expression profiles previously reported for family cohorts of
FSHD1-derived and healthy myocytes [12,36]. We conclude
that this cohort of cell lines maintains the disease specificity
and individual variability of DUX4-fl mRNA expression
profiles typical of FSHD families.
In myocytes, DNA methylation at the 4q35 D4Z4 arrays
typically correlates with DUX4-fl expression levels; healthy
myocytes display D4Z4 hypermethylation and express very low
or undetectable levels of DUX4-fl mRNA, while FSHD1
myocytes are hypomethylated on the contracted allele and
typically express significantly higher levels of DUX4-fl mRNA
[12,31,36].As expected, the healthy LCLs in this cohort showed
a similar correlation, with DNA hypermethylation at the 4q35
D4Z4 array and correspondingly low or undetectable levels of
DUX4-fl (Table S1). Intriguingly, the five DUX4-fl expressing
healthy LCLs, described above, all have healthy levels of DNA
methylation on both 4q D4Z4 arrays (>35% methylated). It is
interesting that these five lines represent only three families
(GM16276 and GM16280 in Family 2; GM16431 and
GM16100 in Family 32; GM16290 in Family 4), suggesting
that these families may have interesting modifier mutations that
affect DUX4-fl expression levels independent of DNA
methylation levels.
Surprisingly, levels of DUX4-fl mRNA in FSHD1 LCLs did
not necessarily correlate with levels of DNA methylation at the
contracted 4qA allele (Table S1). The top five DUX4-fl
expressing lines exhibited extreme DNA hypomethylation as
expected (GM16414, 6.0%; GM16334, 1.8%; GM16336,
5.54%; GM16307, 0.0%; GM16267, 7.1%); however, there are
several striking inconsistencies throughout the cohort. For
example, in Family 6, GM16297 and GM16298 both exhibit
7.1% DNA methylation on the contracted allele, yet there is
a >100-fold difference in DUX4-fl expression between the two
cell lines, again suggesting the presence of genetic modifiers of
DUX4-fl expression in this family. In contrast, Family 18
behaves exactly as expected, with the three FSHD1 lines (18 kb
D4Z4 contraction) exhibiting DNA hypomethylation of the
contracted allele coupled with very high DUX4-fl expression,
while the healthy cell line was hypermethylated with nearly
undetectable levels of DUX4-fl mRNA (Table 1 and Table S1,
Fig. 8, Figs. A.3 and A.4). These data suggest that there are no
FSHD modifying mutations in this family. Overall, the FSHD1
LCLs showed more variability in DNA methylation at the
4q35 D4Z4 array, often extending above the diagnostic
threshold of 35% methylation, than we have seen in primary
cells (myocytes, white blood cells, or saliva). Since we do not
have a source of primary cells from the same individuals to
compare with, it is not clear if these methylation levels are
true representations of each donor individual or are a result of
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Fig. 8. FSHD1 lymphoblastoid cell lines express variable levels of DUX4-fl. DUX4-fl mRNA levels were determined by qRT-PCR and normalized to levels of 18S
RNA. The lowest expressing FSHD sample in each family or group was set to 1 and relative expression levels are shown in each graph. See Table 1 for a relative
comparison of DUX4-fl expression across all LCLs.
233T.I. Jones et al. /Neuromuscular Disorders 27 (2017) 221–238
immortalization, cell culturing, modifier mutations, or some
combination of these factors. Regardless, it is important for the
design of future experiments to know the relationship between
DNA methylation and DUX4-fl expression as we have
documented it for each of these cell lines (Table 1 and Table S1
and Fig. A.4).
The DUX4-FL protein is a transcription factor and its
aberrant expression in FSHD leads to aberrant expression of
its downstream target genes, with consequent pathology
[55,61–67]. To determine if DUX4-mediated aberrant gene
regulation occurs in our cohorts of FSHD1 LCLs, we analyzed
the expression levels of three robustly upregulated DUX4-FL
target genes, ZSCAN4, TRIM43, and MBD3L2 [55], in 30 cell
lines from Families 2, 4, and 25 (Fig. 9). Similar to DUX4-fl
expression, the expression levels of these target genes were
highly variable between the 15 FSHD1 cell lines analyzed.
However, for each cell line, the relative expression level of each
target gene precisely correlated with the relative level ofDUX4-
fl, supporting the likelihood that DUX4-FL induces expression
of its target genes in these cells. Similarly, in the healthy cell
lines, the levels of these target genes correlated with the levels
of DUX4-fl and were very low in 13/15 lines. Only two of the
healthy cell lines, GM16276 and GM16295, displayed
appreciable expression of the target genes without detectable
DUX4-fl expression. We conclude that, as with FSHD
myocytes, these FSHD LCLs aberrantly express DUX4-FL
protein, which functions as a transcriptional activator of its
direct target genes.
3.3. Treatment with inhibitors of epigenetic repression
induces DUX4-fl expression in FSHD1 LCLs
In myogenic cultures, treatment with the DNA
methyltransferase inhibitor 5-aza-2′-deoxycytidine (ADC) and
the histone deacetylase inhibitor Trichostatin A (TSA) induces
DUX4-fl expression in FSHD cells, but not in healthy controls.
To determine if these LCLs respond similarly to epigenetic
drug treatment, we tested 4 FSHD1 and 2 healthy LCLs from
Family 33 (Fig. 10). Combined treatment with ADC and TSA
resulted in very strong induction (up to >3000 fold) of DUX4-fl
expression in all four FSHD1 LCLs, while failing to induce
DUX4-fl to appreciable levels in the two healthy lines. This
responsiveness to ADC and TSA is consistent with what is
Fig. 9. Expression of DUX4-fl in FSHD1 lymphoblastoid cell lines correlates with increased expression of DUX4-FL target genes. mRNA levels of DUX4-fl and
three of its downstream target genes, MBD3L2, TRIM43, and ZSCAN4, were determined by qRT-PCR and normalized to levels of 18S RNA.
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found in FSHD skeletal myocytes; however, the level of
induction is significantly higher in the LCLs. Interestingly, as
with FSHD myocytes [12], cells from asymptomatic subjects
(GM16254 and GM16425) are readily inducible and appear
epigenetically poised to express DUX4-fl. Since ADC can
induce MyoD expression in non-myogenic cell types [68,69]
and DUX4-fl is regulated in part by myogenic factors, we
assayed levels of MyoD and Myogenin in these LCLs; however,
these genes were not induced by the drug treatment (data not
shown). We conclude that the epigenetic regulation of DUX4-fl
expression and repression is maintained in the LCLs.
3.4. Family 33
The analysis of Family 33 (Fig. 7, Table 1) revealed several
unusual characteristics that present interesting opportunities for
further investigation. The FSHD1 deletion analysis indicated
that this family has two different FSHD1 chromosomes, 6RUs
and 9RUs, originating from one parent. Cell lines were
available for 5 of the 7 children and, as expected, all 5 children
contained one of the FSHD1 chromosomes with 4/5 being
clinically diagnosed with FSHD. Overall, the complement of
Family 33 cell lines contains 5 with 6RUs (all from affected
subjects), 5 with 9RUs (2 from affected and 3 from
asymptomatic subjects), and 7 healthy (2 from unaffected
spouses). Thus, both 6RU and 9RU are independently
associated with clinically described FSHD; however, only the
9RU chromosome was found in cell lines from asymptomatic
subjects, consistent with the reported asymptomatic range of
D4Z4 RUs [11,12]. In addition, the three asymptomatic
subjects were all >35 years of age at the time of their clinical
evaluation, with one subject being >65 years old, supporting the
classification of these subjects as asymptomatic. The 9RU
chromosome in this family is particularly interesting because it
has the 4qA166 haplotype, which is typically described in the
literature as nonpermissive despite having an exon 3 PAS. We
confirmed the presence of the PAS and, importantly, the
expression of 4A166-type polyadenylated DUX4-fl mRNA in
all 9RU cell lines by sequencing the RT-PCR product (Fig. A.5)
[35]. Interestingly, two of the 4A166 9RU LCLs (GM16254 and
GM16354) expressed very high levels ofDUX4-flmRNAwhile
another 4A166 9RU LCL (GM16425) expressed the lowest
levels of DUX4-fl mRNA among all 63 FSHD1 lines in the
cohort. Overall, these cell lines from first and second degree
relatives of Family 33 present the opportunity to compare cell
lines from FSHD1 affected, asymptomatic, and healthy
relatives, the differences between 6 and 9RUs in first degree
relatives, and to analyze FSHD1 affected and asymptomatic
cells with the 4A166 haplotype.
4. Discussion
The goal of this study was to perform an initial
characterization of 114 LCLs long held out of circulation due to
a lack of characterization, which would allow these valuable
resources to be made freely available to the FSHD community
through the NIGMS Human Genetic Cell Repository at the
CIMR repository, where they have been held in cryostorage.
This study does not represent a complete characterization of the
cell lines; for example, determining the sizes of both 4q and 10q
D4Z4 arrays for each cell line or the genetic status of SMCHD1,
mutations in which can be causal for FSHD2 and modify
severity of FSHD1, was beyond our capabilities and outside the
scope of this study [8,9,11]. Because the original clinical
samples were collected prior to genetic testing for FSHD, we
decided, in consultation with officials at CIMR, to confirm the
identity of each cell line with respect to the pedigree, identify
those with FSHD1-sized deletions or FSHD2-type DNA
hypomethylation, determine 4q and 10q SSLPs and
subtelomere haplotypes, and assess the presence or absence of
an exon 3 PAS. We have successfully completed this analysis
for all LCLs and provided the information to CIMR, thus
making these cells immediately available to the research
community through their online catalog.
One notable omission for these LCLs is information on the
clinical characteristics, specific methods for evaluation, and
specific diagnostic criteria used for each of the individual
subjects from which they were derived. Multiple clinicians
across the United States examined these subjects and their
family members, and ultimately >600 clinical samples were
obtained from at least 36 families, with numerous subjects
across generations clinically diagnosed with FSHD; however,
many samples were lost over time, some subjects were not
available for reconsent, and most of the specific clinician notes
Fig. 10. DUX4-fl mRNA is induced in FSHD1 LCLs, but not in healthy controls, by treatment with epigenetic drugs. LCLs from Family 33 were treated (+) or not
treated (NT) with 5-aza-2′-deoxycytidine (ADC) and Trichostatin A (TSA). DUX4-fl mRNA levels were determined by qRT-PCR and normalized to levels of 18S
RNA. The lowest expressing NT FSHD1 sample (GM16126) is set to 1.
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were lost or destroyed. For the samples that remained, the only
clinical information available was the final clinical assessment
of “FSHD”; the specific measurements and criteria for each
individual (e.g., which muscles were affected, clinical severity,
or level of weakness) are not known. However, an FSHD study
performed by Dr. Jacobsen and colleagues, who obtained the
Utah samples described in our current study and published soon
thereafter, describes the clinical assessment used for FSHD
subjects [44]. The criteria for FSHD were: (1) inheritance
consistent with autosomal dominant genetics, (2) muscle
weakness of at least one of several specific muscles of the face
and shoulder girdle, and (3) muscle atrophy by the age of 20
years in at least one affected family member [44]. When
matched with our blinded genetic testing, the original clinical
diagnosis for FSHD was 12/12 with respect to families (all are,
in fact, now known to be genetically FSHD families) and five
families (2, 7, 12, 18, and 36) had a 100% match between the
clinical and our genetic diagnosis for healthy and FSHD. Out of
a total of 63 genetically defined FSHD1 subjects, 55 showed
clinical FSHD and 8 are designated as asymptomatic (lacking
clinical symptoms at the time of their assessment). We feel that
the designation of asymptomatic is accurate, since these 8
subjects were examined by neurologists specifically looking for
signs of clinical FSHD in families affected by the disease.
This information, as with all FSHD asymptomatic or non-
manifesting diagnoses, comes with the caveat that these
subjects may have developed FSHD at a later time in their lives.
Interestingly, 5 subjects (GM16290, GM16299, GM16322,
GM16324, and GM16431) clinically characterized as FSHD
were found not to contain an FSHD1-sized deletion.
Unfortunately, in the absence of more detailed notes we can
only speculate on the reasons for this discrepancy. However,
since these subjects represent 4 different families (Families 4, 6,
11, and 32) not known to be related and all exhibit DNA
methylation levels well within the range for healthy subjects,
these cases likely represent over-interpretation of clinical signs.
Alternatively, one or more of these could represent clinical
mis-classification of a neuromuscular disease phenocopy of
FSHD, but a second rare disorder spontaneously arising in even
one of the families is highly unlikely. Now that nearly 30 years
has passed, a potential follow-up study of all of these subjects
would be extremely interesting and informative.
In addition to the minimal information required to make
these LCLs available, we also collected data that would be
important and useful for making decisions on which cell lines
to use for different lines of investigation relevant to FSHD. As
DUX4-fl expression in skeletal muscle is the key pathogenic
consequence of the epigenetic disruption in FSHD, it stands to
reason that DUX4-fl expression is typically and best studied in
myogenic cells. Thus, the relevance of LCLs for assaying
DUX4 expression has been in question. Here we show that
FSHD1 lymphoblastoid lines are clearly capable of expressing
DUX4-fl mRNA and protein, with consequent expression of
several DUX4-FL target genes that are also activated in
myocytes. Additionally, as with FSHD myocytes, epigenetic
drugs readily induce high levels of DUX4-fl in these FSHD1
LCLs, suggesting that these cells may be useful for studies
investigating or manipulating the epigenetic status of the 4q35
D4Z4 array. Importantly, we confirmed that only genetically
FSHD1 LCLs express significant levels of DUX4-fl mRNA;
however, the variable levels of DUX4-fl expression across 63
FSHD1 lines, many with the same deletion, might help to
explain the variable success labs have reported with
lymphoblastoid cell lines. Surprisingly, we typically found a
range of >100-fold differences in DUX4-fl expression levels in
FSHD1 LCLs within families. We do not know the underlying
cause of this variability, which would represent an interesting
follow-up study, but a knowledge of these differences is
important for the planning of future experiments.
5. Conclusions
We have provided a preliminary genetic and molecular
characterization of 114 LCLs from 12 FSHD1 affected
families, enabling these cell lines to become publicly available
for use by the FSHD field. We have also provided additional
evidence that this cohort of cells will be a valuable resource for
investigating many aspects of gene expression and regulation in
FSHD. We recognize that FSHD is a muscle disease and
investigating FSHD in myogenic cells is important; however,
there are limitations imposed by working with primary
differentiated myogenic cells, and alternative models are
needed. We propose that these LCLs may fill this need, serving
as a tool enabling high-throughput screening of therapeutics
targeting DUX4 expression.
Funding
This work was funded by the National Institute of Arthritis
and Musculoskeletal and Skin Diseases [grant number
1R01AR062587], the FSH Society [grant number FSHS-2015-
SG02], and the OCTV Technology Development Fund at
the University of Massachusetts. The FSH Society initiated
the project and facilitated the work through its completion. The
funders played no role in the data analysis or interpretation.
Author contributions
Takako Jones: Drafting/revising the manuscript; study
concept and design; acquisition and analysis of data.
Charis Himeda: Drafting/revising the manuscript; study
design; acquisition and analysis of data.
Daniel Perez: Drafting/revising the manuscript; study
concept, coordination and design; interfacing with clinicians,
patients, families, and Coriell Biorepositories; obtaining
bioresources.
Peter Jones: Drafting/revising the manuscript; study concept
and design; acquisition and analysis of data.
All authors approved the final manuscript.
Acknowledgements
We are grateful to these families for participating in the
study. We thank Dr. Stephen Jacobsen for clinically evaluating
many of the subjects and collecting the clinical samples, and the
NIGMS Human Genetic Cell Repository at the Coriell Institute
for Medical Research repository for culturing, maintaining, and
236 T.I. Jones et al. /Neuromuscular Disorders 27 (2017) 221–238
distributing the cell lines. We thank Dr. Yukiko K. Hayashi,
Department of Neurophysiology, Tokyo Medical University, for
sharing the protocol for linear southern blotting analysis.
Appendix: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.nmd.2016.12.007.
References
[1] Padberg GW. Facioscapulohumeral Disease [thesis]. Leiden University:
Leiden, the Netherlands. p. 243; 1982.
[2] Flanigan KM. The muscular dystrophies. Semin Neurol 2012;32:255–63.
[3] Orphanet. Prevalence and incidence of rare diseases: Bibliographic data.
Orphanet Report Series: Rare Diseases collection; 2016. Available from:
http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare
_diseases_by_alphabetical_list.pdf [Accessed October 2016].
[4] Deenen JC, Arnts H, van der Maarel SM, et al. Population-based
incidence and prevalence of facioscapulohumeral dystrophy. Neurology
2014;83:1056–9.
[5] Wang LH, Tawil R. Facioscapulohumeral Dystrophy. Curr Neurol
Neurosci Rep 2016;16:66.
[6] Padberg GW, van Engelen BG. Facioscapulohumeral muscular dystrophy.
Curr Opin Neurol 2009;22:539–42.
[7] de Greef JC, Lemmers RJ, van Engelen BG, et al. Common epigenetic
changes of D4Z4 in contraction-dependent and contraction-independent
FSHD. Hum Mutat 2009;30:1449–59.
[8] Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an
SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes
facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012;44:
1370–4.
[9] Sacconi S, Lemmers RJ, Balog J, et al. The FSHD2 gene SMCHD1 is a
modifier of disease severity in families affected by FSHD1. Am J Hum
Genet 2013;93:744–51.
[10] Larsen M, Rost S, El Hajj N, et al. Diagnostic approach for FSHD
revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of
disease severity in FSHD1. Eur J Hum Genet 2014;23:808–16.
[11] Lemmers RJ, Goeman JJ, Van Der Vliet PJ, et al. Inter-individual
differences in CpG methylation at D4Z4 correlate with clinical variability
in FSHD1 and FSHD2. Hum Mol Genet 2015;24:659–69.
[12] Jones TI, King OD, Himeda CL, et al. Individual epigenetic status of
the pathogenic D4Z4 macrosatellite correlates with disease in
facioscapulohumeral muscular dystrophy. Clin Epigenetics 2015;7:37.
[13] Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RC, Passos-Bueno
MR. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects
males more severely and more frequently than females. Am J Med Genet
1998;77:155–61.
[14] Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R,
Zatz M. Asymptomatic carriers and gender differences in
facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord
2004;14:33–8.
[15] Himeda CL, Jones TI, Jones PL. Facioscapulohumeral muscular
dystrophy as a model for epigenetic regulation and disease. Antioxid
Redox Signal 2015;22:1463–82.
[16] Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA
rearrangements associated with facioscapulohumeral muscular dystrophy.
Nat Genet 1992;2:26–30.
[17] van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. FSHD
associated DNA rearrangements are due to deletions of integral copies of
a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993;2:2037–42.
[18] Schaap M, Lemmers RJ, Maassen R, et al. Genome-wide analysis of
macrosatellite repeat copy number variation in worldwide populations:
evidence for differences and commonalities in size distributions and size
restrictions. BMC Genomics 2013;14:143.
[19] Rossi M, Ricci E, Colantoni L, et al. The Facioscapulohumeral muscular
dystrophy region on 4qter and the homologous locus on 10qter evolved
independently under different evolutionary pressure. BMC Med Genet
2007;8:8.
[20] Tyler FH, Stephens FE. Studies in disorders of muscle. II Clinical
manifestations and inheritance of facioscapulohumeral dystrophy in a
large family. Ann Intern Med 1950;32:640–60.
[21] Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral
muscular dystrophy is uniquely associated with one of the two variants of
the 4q subtelomere. Nat Genet 2002;32:235–6.
[22] Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. Specific sequence
variations within the 4q35 region are associated with facioscapulohumeral
muscular dystrophy. Am J Hum Genet 2007;81:884–94.
[23] Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model
for facioscapulohumeral muscular dystrophy. Science 2010;329:1650–3.
[24] de Greef JC, Lemmers RJ, Camano P, et al. Clinical features of
facioscapulohumeral muscular dystrophy 2. Neurology 2010;75:1548–54.
[25] van den Boogaard ML, Lemmers RJ, Balog J, et al. Mutations in
DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the
Penetrance of Facioscapulohumeral Dystrophy. Am J Hum Genet
2016;98:1020–9.
[26] van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of
D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular
dystrophy. Nat Genet 2003;35:315–17.
[27] van Overveld PG, Enthoven L, Ricci E, et al. Variable hypomethylation of
D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol
2005;58:569–76.
[28] Zeng W, de Greef JC, Chen YY, et al. Specific loss of histone H3 lysine
9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is
associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet
2009;5:e1000559.
[29] Balog J, Thijssen PE, de Greef JC, et al. Correlation analysis of clinical
parameters with epigenetic modifications in the DUX4 promoter in
FSHD. Epigenetics 2012;7:1–6.
[30] Calandra P, Cascino I, Lemmers RJ, et al. Allele-specific DNA
hypomethylation characterises FSHD1 and FSHD2. J Med Genet
2016;53:348–55.
[31] Jones TI, Yan C, Sapp PC, et al. Identifying diagnostic DNA methylation
profiles for facioscapulohumeral muscular dystrophy in blood and saliva
using bisulfite sequencing. Clin Epigenetics 2014;6:23.
[32] Gaillard MC, Roche S, Dion C, et al. Differential DNA methylation of the
D4Z4 repeat in patients with FSHD and asymptomatic carriers.
Neurology 2014;83:733–42.
[33] Gabriels J, Beckers MC, Ding H, et al. Nucleotide sequence of the
partially deleted D4Z4 locus in a patient with FSHD identifies a putative
gene within each 3.3 kb element. Gene 1999;236:25–32.
[34] Dixit M, Ansseau E, Tassin A, et al. DUX4, a candidate gene of
facioscapulohumeral muscular dystrophy, encodes a transcriptional
activator of PITX1. Proc Natl Acad Sci USA 2007;104:18157–62.
[35] Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy:
incomplete suppression of a retrotransposed gene. PLoS Genet
2010;6:e1001181.
[36] Jones TI, Chen JC, Rahimov F, et al. Facioscapulohumeral muscular
dystrophy family studies of DUX4 expression: evidence for disease
modifiers and a quantitative model of pathogenesis. Hum Mol Genet
2012;21:4419–30.
[37] Himeda CL, Debarnot C, Homma S, et al. Myogenic enhancers regulate
expression of the facioscapulohumeral muscular dystrophy associated
DUX4 gene. Mol Cell Biol 2014;34:1942–55.
[38] van der Maarel SM, Miller DG, Tawil R, Filippova GN, Tapscott SJ.
Facioscapulohumeral muscular dystrophy: consequences of chromatin
relaxation. Curr Opin Neurol 2012;25:614–20.
[39] Lemmers RJ, Wohlgemuth M, Frants RR, Padberg GW, Morava E, van
der Maarel SM. Contractions of D4Z4 on 4qB subtelomeres do not
cause facioscapulohumeral muscular dystrophy. Am J Hum Genet
2004;75:1124–30.
[40] Lemmers RJ, van der Vliet PJ, van der Gaag KJ, et al. Worldwide
population analysis of the 4q and 10q subtelomeres identifies only four
discrete interchromosomal sequence transfers in human evolution. Am J
Hum Genet 2010;86:364–77.
237T.I. Jones et al. /Neuromuscular Disorders 27 (2017) 221–238
[41] Vanderplanck C, Ansseau E, Charron S, et al. The FSHD Atrophic
Myotube Phenotype Is Caused by DUX4 Expression. PLoS ONE
2011;6:e26820.
[42] Marsollier AC, Ciszewski L, Mariot V, et al. Antisense targeting of 3’ end
elements involved in DUX4 mRNA processing is an efficient therapeutic
strategy for facioscapulohumeral dystrophy: a new gene-silencing
approach. Hum Mol Genet 2016;25:1468–78.
[43] Himeda CL, Jones TI, Jones PL. CRISPR/dCas9-mediated
Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at
D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy. Mol Ther
2016;24:527–35.
[44] Jacobsen SJ, Diala ES, Dorsey BV, et al. A clinically homogeneous group
of families with facioscapulohumeral (Landouzy-Dejerine) muscular
dystrophy: linkage analysis of six autosomes. Am J Hum Genet
1990;47:376–88.
[45] Sarfarazi M, Wijmenga C, Upadhyaya M, et al. Regional mapping of
facioscapulohumeral muscular dystrophy gene on 4q35: combined
analysis of an international consortium. Am J Hum Genet
1992;51:396–403.
[46] Weiffenbach B, Bagley R, Falls K, et al. Linkage analyses of five
chromosome 4 markers localizes the facioscapulohumeral muscular
dystrophy (FSHD) gene to distal 4q35. Am J Hum Genet
1992;51:416–23.
[47] Weiffenbach B, Dubois J, Storvick D, et al. Mapping the
facioscapulohumeral muscular dystrophy gene is complicated by
chromosome 4q35 recombination events. Nat Genet 1993;4:165–9.
[48] Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF.
Genetic characterization of a large, historically significant Utah
kindred with facioscapulohumeral dystrophy. Neuromuscul Disord
2001;11:525–9.
[49] Goto K, Nishino I, Hayashi YK. Very low penetrance in 85 Japanese
families with facioscapulohumeral muscular dystrophy 1A. J Med Genet
2004;41:e12.
[50] Deidda G, Cacurri S, Piazzo N, Felicetti L. Direct detection of 4q35
rearrangements implicated in facioscapulohumeral muscular dystrophy
(FSHD). J Med Genet 1996;33:361–5.
[51] Lemmers RJL, de Kievit P, van Geel M, et al. Complete allele information
in the diagnosis of facioscapulohumeral muscular dystrophy by triple
DNA analysis. Ann Neurol 2001;50:816–19.
[52] Rohde C, Zhang Y, Reinhardt R, Jeltsch A. BISMA – fast and accurate
bisulfite sequencing data analysis of individual clones from unique and
repetitive sequences. BMC Bioinformatics 2010;11:230.
[53] Barat-Houari M, Nguyen K, Bernard R, et al. New multiplex PCR-based
protocol allowing indirect diagnosis of FSHD on single cells: can PGD be
offered despite high risk of recombination? Eur J Hum Genet
2010;18:533–8.
[54] Mannucci A, Sullivan KM, Ivanov PL, Gill P. Forensic application of a
rapid and quantitative DNA sex test by amplification of the X-Y
homologous gene amelogenin. Int J Legal Med 1994;106:190–3.
[55] Geng LN, Yao Z, Snider L, et al. DUX4 activates germline genes,
retroelements, and immune mediators: implications for
facioscapulohumeral dystrophy. Dev Cell 2012;22:38–51.
[56] Bakker E, Wijmenga C, Vossen RH, et al. The FSHD-linked locus
D4F104S1 (p13E-11) on 4q35 has a homologue on 10qter. Muscle Nerve
1995;2:S39–44.
[57] Daxinger L, Tapscott SJ, van der Maarel SM. Genetic and epigenetic
contributors to FSHD. Curr Opin Genet Dev 2015;33:56–61.
[58] Caliskan M, Cusanovich DA, Ober C, Gilad Y. The effects of EBV
transformation on gene expression levels and methylation profiles. Hum
Mol Genet 2011;20:1643–52.
[59] Sugawara H, Iwamoto K, Bundo M, Ueda J, Ishigooka J, Kato T.
Comprehensive DNA methylation analysis of human peripheral blood
leukocytes and lymphoblastoid cell lines. Epigenetics 2011;6:508–15.
[60] Thompson TM, Sharfi D, Lee M, Yrigollen CM, Naumova OY,
Grigorenko EL. Comparison of whole-genome DNA methylation patterns
in whole blood, saliva, and lymphoblastoid cell lines. Behav Genet
2013;43:168–76.
[61] Krom YD, Thijssen PE, Young JM, et al. Intrinsic Epigenetic Regulation
of the D4Z4 Macrosatellite Repeat in a Transgenic Mouse Model for
FSHD. PLoS Genet 2013;9:e1003415.
[62] Yao Z, Snider L, Balog J, et al. DUX4-induced gene expression is the
major molecular signature in FSHD skeletal muscle. Hum Mol Genet
2014;23:5342–52.
[63] Choi SH, Gearhart MD, Cui Z, et al. DUX4 recruits p300/CBP through its
C-terminus and induces global H3K27 acetylation changes. NucleicAcids
Res 2016;44(11):5161–73.
[64] Wuebbles RD, Long SW, Hanel ML, Jones PL. Testing the effects of
FSHD candidate gene expression in vertebrate muscle development. Int J
Clin Exp Pathol 2010;3:386–400.
[65] Wallace LM, Garwick SE, Mei W, et al. DUX4, a candidate gene for
facioscapulohumeral muscular dystrophy, causes p53-dependent
myopathy in vivo. Ann Neurol 2011;69:540–52.
[66] Rickard AM, Petek LM, Miller DG. Endogenous DUX4 expression in
FSHD myotubes is sufficient to cause cell death and disrupts RNA
splicing and cell migration pathways. Hum Mol Genet 2015;24:5901–14.
[67] Homma S, Beermann ML, Boyce FM, Miller JB. Expression of
FSHD-related DUX4-FL alters proteostasis and induces TDP-43
aggregation. Ann Clin Transl Neurol 2015;2:151–66.
[68] Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and
3T3 cells treated with 5-azacytidine. Cell 1979;17:771–9.
[69] Tapscott SJ. The circuitry of a master switch: myod and the regulation of
skeletal muscle gene transcription. Development 2005;132:2685–95.
238 T.I. Jones et al. /Neuromuscular Disorders 27 (2017) 221–238
